A Phase 3b Multicenter Randomized Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Activ

Brief description of study

The purpose of this study is to see if guselkumab is safe and useful for treating patients with active psoriatic arthritis (PSA). Guselkumab is a type of drug called a monoclonal antibody. An antibody is a protein in the immune system that protects against invaders like bacteria and viruses, but can also block protein function. A monoclonal antibody is made in a laboratory. Guselkumab attaches to part of a protein called interleukin (IL)-23 to block it from causing inflammatory processes from happening. We want to see if guselkumab will improve the signs and symptoms of PSA and slow or stop the disease progression in the joints.

Clinical Study Identifier: s20-02015
ClinicalTrials.gov Identifier: NCT04882098
Principal Investigator: David H. Goddard.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.